-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – APG-5918 in Sarcomas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.APG-5918 in Sarcomas Drug Details:APG-5918 is under development for the treatment of beta-thalassemia, metastatic solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – APG-157 in Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. APG-157 in Squamous Cell Carcinoma Drug Details: APG-157Â is under development for the treatment of recurrent...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – APG-5918 in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.APG-5918 in Gastric Cancer Drug Details:APG-5918 is under development for the treatment of beta-thalassemia, metastatic solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – APG-5918 in Malignant Mesothelioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.APG-5918 in Malignant Mesothelioma Drug Details:APG-5918 is under development for the treatment of beta-thalassemia, metastatic solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – APG-157 in Oropharyngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. APG-157 in Oropharyngeal Cancer Drug Details: APG-157Â is under development for the treatment of recurrent high-grade...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – APG-5918 in Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.APG-5918 in Ovarian Cancer Drug Details:APG-5918 is under development for the treatment of beta-thalassemia, metastatic solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – APG-5918 in Nasopharyngeal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.APG-5918 in Nasopharyngeal CancerDrug Details:APG-5918 is under development for the treatment of beta-thalassemia, metastatic solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – APG-1387 in Blood Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. APG-1387 in Blood Cancer Drug Details: APG-1387 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – APG-1387 in Nasopharyngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. APG-1387 in Nasopharyngeal Cancer Drug Details: APG-1387 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – APG-2449 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. APG-2449 in Ovarian Cancer Drug Details: APG-2449 is under development for the treatment of relapsed...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.